Edwards Lifesciences vs Takeda Pharmaceutical
Edwards Lifesciences (EW), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Takeda Pharmaceutical is worth $69.3B on the stock market and Edwards Lifesciences $61.8B: Takeda Pharmaceutical is valued at 12% more. Edwards Lifesciences trades at 62.5 times earnings and Takeda Pharmaceutical at 310; operating margins in their latest fiscal years were 20.8% and 0.14%. Over the past year Edwards Lifesciences's share price has moved +27.5% and Takeda Pharmaceutical's +53.4%.
Key facts
- Edwards Lifesciences market value
- $61.8B
- Takeda Pharmaceutical market value
- $69.3B
- Edwards Lifesciences P/E
- 62.5
- Takeda Pharmaceutical P/E
- 310
- Edwards Lifesciences revenue
- $6.1BFY to 2025-12-31
- Takeda Pharmaceutical revenue
- $28.2BFY to 2026-03-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Edwards Lifesciences | Takeda Pharmaceutical |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $61.8Blower | $69.3Bhigher |
| Revenue | $6.1Blower | $28.2Bhigher |
| Earnings | $1.1Bhigher | -$954.4Mlower |
| Employees | 16,000lower | 47,029higher |
| Total assets | $13.7Blower | $97.1Bhigher |
| Valuation | ||
| P/E | 62.5lower | 310higher |
| P/S | 10.2higher | 2.5lower |
| P/B | 5.7 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 20.8%higher | 0.14%lower |
| Balance sheet | ||
| Net assets | $10.3Blower | $46.5Bhigher |
| Total liabilities | $3.4Blower | $50.6Bhigher |
| Total debt | $598.3Mlower | $30.6Bhigher |
| Cash on hand | $2.9Blower | $3.7Bhigher |
| Price change | ||
| Today | +0.29%lower | +0.46%higher |
| 1 year | +27.5%lower | +53.4%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Edwards Lifesciences only (9)
- David Rolfe3.1%
- Howard Gleicher1.6%
- Brandon Haley0.7%
- Steve Cohen0.2%
- Israel Englander0.2%
- Ken Griffin0.2%
- Primecap team0.2%
- Baillie Gifford team0.1%
- Ron Baron0.1%
Takeda Pharmaceutical only (2)
Percentages are each holding's share of that investor's reported portfolio. Who owns EW · Who owns TAK
More on Edwards Lifesciences
Further comparisons
Edwards Lifesciences against its closest peers
Takeda Pharmaceutical against its closest peers
Learn
Questions and answers
Which is bigger, Edwards Lifesciences or Takeda Pharmaceutical?
By market value, Takeda Pharmaceutical is the larger: $69.3B against $61.8B for Edwards Lifesciences. By revenue in its latest fiscal year, Takeda Pharmaceutical is the larger: $28.2B against $6.1B for Edwards Lifesciences.
Which has the higher P/E ratio?
Takeda Pharmaceutical: 310, against 62.5 for Edwards Lifesciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Edwards Lifesciences: 20.8%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Takeda Pharmaceutical: $30.6B, against $598.3M for Edwards Lifesciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Edwards Lifesciences and Takeda Pharmaceutical?
None of the tracked superinvestors holds both in their latest 13F filing. 9 hold Edwards Lifesciences and 2 hold Takeda Pharmaceutical.
Cite this page
Funkfolio, “Edwards Lifesciences vs Takeda Pharmaceutical”, data as of 17 November 2026. https://funkfolio.com/compare/ew-vs-tak
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.